Tirzepatide oral form: separating fact from the rumours circulating online

The misconception: tirzepatide must come as a pill because semaglutide now does

The arrival of oral GLP-1 treatment in the UK has blurred a lot of people's understanding of what is and isn't available. On 11 June 2026 the MHRA approved Wegovy tablets (oral semaglutide) as the first licensed oral GLP-1 medicine for weight management in the UK. That approval, widely reported, led to a surge in searches asking whether tirzepatide had gone the same route. It hasn't. Tirzepatide and semaglutide are related but distinct molecules. Semaglutide activates a single gut-hormone receptor (GLP-1); tirzepatide, the active ingredient in Mounjaro, activates two (GIP and GLP-1), which is part of what makes its pharmacology different and also makes oral bioavailability a more complex engineering problem. Eli Lilly has published research into oral tirzepatide formulations, but as of summer 2026 no version has received MHRA authorisation for use in the UK. The injection is the only licensed form.

Check the Electronic Medicines Compendium if you want to verify which forms of any medicine hold UK marketing authorisation, it takes under a minute and lists every approved product by name, form and strength. You won't find a tirzepatide tablet or drop there.

What's actually being sold as 'oral tirzepatide', and why it matters

Searches for oral tirzepatide online turn up a variety of products: sublingual drops, troches, capsules, compounded lozenges. None of these hold MHRA marketing authorisation. Some are sold by overseas compounding pharmacies or social-media vendors who present them as equivalent to the injected product. They are not. The MHRA has been clear that GLP-1 medicines bought without a prescription from unverified sources carry serious safety risks, fake or unlicensed products have in some cases contained entirely the wrong active ingredient. Legitimate weight-loss treatment through a GPhC-registered pharmacy in the UK means verified product from the licensed supply chain, dispensed against a valid prescription. If a website offers you tirzepatide in oral form and claims it is equivalent to Mounjaro, that should be treated as a red flag, not a convenience. You can check any UK pharmacy's registration on the GPhC register before handing over personal or payment details.

For context on how the counterfeit and unlicensed medicine problem has grown, the MHRA's guidance on GLP-1 medicines for weight loss (GOV.UK) sets out what genuine supply looks like and what to watch for.

The oral option that IS licensed in the UK: what to know before assuming it's the same thing

If you prefer not to self-inject, there is now a real, MHRA-approved oral option for weight management: Wegovy tablets (oral semaglutide). These work through the GLP-1 pathway alone and follow a different dosing schedule to the injection, starting at 1.5mg daily and titrating up to a 25mg maintenance dose, taken first thing in the morning on an empty stomach with a small amount of water, at least 30 minutes before food or other medicines. Trial data from OASIS 4 (64 weeks, 307 adults with obesity or overweight) showed around 13.6% average weight loss versus approximately 2.4% on placebo; among participants who stayed fully adherent the figure was closer to 17%. These results are meaningful, though they sit below the averages seen with injectable tirzepatide in head-to-head comparisons of the trial programmes. Wegovy tablets require no refrigeration, which some people find practical for travel or everyday storage. Whether the tablet or the injection suits you better is genuinely a clinical question (efficacy, tolerability, your medical history and your preferences all factor in) and that is exactly what a prescriber works through with you. See our treatment pricing page for an honest look at what private weight-loss treatment costs in the UK.

If tirzepatide is right for you, this is how it works in practice

Licensed tirzepatide treatment (the KwikPen injection) is a once-weekly dose you give yourself subcutaneously, rotating between the abdomen, thigh and upper arm. Treatment starts at 2.5mg, a dose designed to let your body adjust before any therapeutic increase. A prescriber titrates the dose from there, typically in four-week steps, up through 5, 7.5, 10, 12.5 and 15mg. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average weight reductions of around 20–21% at 15mg over 72 weeks, figures that led NICE to recommend tirzepatide for eligible adults in its appraisal TA1026. Most common side effects are gastrointestinal: nausea, loose stools, indigestion. These tend to be most noticeable after starting or a dose step, and usually settle. A detailed breakdown of the full tirzepatide profile covers eligibility, evidence and side effects more thoroughly. If you're unsure which treatment fits your situation, our prescribers at the nume clinical team a real clinician reads your consultation the same day, not an automated queue. Start your free consultation to find out what's clinically appropriate for you.